Programmable in-vivo nanodevices
Nanometre-to-micron scale devices that circulate in the body, sense their surroundings, make a decision and act on a target cell.
State of the art
pH-triggered DNA-origami nanorobots cut mouse tumor growth by about 70 percent (2024); magnetically actuated microrobots are navigable under photoacoustic and MRI guidance in animal models; reviews in 2025 report no clinical applications yet.
- No onboard power source or computation - behavior is limited to a single preset molecular trigger
- Immune clearance and protein-corona formation remove most devices within hours
- Actuation cannot overcome blood flow or cross tissue barriers on command
- External actuation rigs used in labs do not fit clinical imaging suites
Who’s working on it
- Bjorn HogbergResearcherKarolinska Institutet
His pH-triggered DNA-origami nanorobot displaying death-receptor peptides cut breast-cancer xenograft growth by about 70 percent (2024)
- Bradley NelsonResearcherETH Zurich
Senior author of Clinically ready magnetic microrobots for targeted therapies (Science, November 2025), carrying thrombolytics, antibiotics or tumour drugs and tested in pigs
- Hao YanResearcherArizona State University
Built the thrombin-releasing DNA origami nanorobot that shuts down tumour blood supply, reported immunologically inert in mice and miniature pigs
- Nanoflex RoboticsStartup
ETH Zurich spin-off commercialising the magnetic navigation hardware needed to steer devices from inside a clinical imaging suite
- Bionaut LabsStartup
Raised 43 million dollars in 2022 and holds FDA humanitarian use device designation for BNL-201, a magnetically driven brain microrobot, still preclinical as of 2026
- Max Planck Institute for Intelligent SystemsAcademic lab
Source of the microrobot drug-delivery technology Bionaut licensed, and a continuing centre for untethered medical microrobot research
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| research | Chemical logic and energy-harvesting modules giving devices multi-step conditional behavior in serum | $$ $10M – $100M |
| engineering | Clinically compatible actuation and tracking systems (MRI-integrated magnetic steering) with closed-loop control | $$$ $100M – $1B |